Antibiotic Treatment Strategies for Helicobacter pylori Infection

Campo, Salvatore Maria Antonio; Zullo, Angelo; Hassan, Cesare; Morini, Sergio

doi:10.2174/157489107779561706

Cited by 23 publications

(10 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is thought that only new classes of antimicrobials with novel mechanisms of action can fully address the increasing drug resistance 29. In the last decade, several patents of new antibiotics have claimed potential activity against H. pylori 30–32. Of note, some molecules have shown a very high bactericidal level of activity against H. pylori in vitro, including those strains with primary clarithromycin and/or metronidazole resistance.…”

Section: Future Therapiesmentioning

confidence: 99%

Newer agents for Helicobacter pylori eradication

Fiorini

Zullo²,

Gatta³

et al. 2012

CEG

View full text Add to dashboard Cite

Helicobacter pylori infection remains widespread internationally, with a definite morbidity and mortality. The efficacy of standard 7–14 day triple therapies is decreasing, mainly due to increasing primary bacterial resistance to antibiotics. Currently, the most effective treatments are either the sequential regimen or the concomitant therapy. Different patents have been registered showing high bactericidal effects in vitro, some of which are active against clarithromycin- and metronidazole-resistant strains, even at low pH values. Among these novel molecules, benzimidazole-derivatives, polycyclic compounds, pyloricidin, and arylthiazole analogues seem to be the more promising. The identification of essential genes for either bacterial colonization or growth represents a route for potential target therapies in the near future.

show abstract

Section: Future Therapiesmentioning

confidence: 99%

Newer agents for Helicobacter pylori eradication

Fiorini

Zullo²,

Gatta³

et al. 2012

CEG

View full text Add to dashboard Cite

show abstract

“…These enzymes may represent an attractive target for H. pylori therapy in the future. Newer antibiotics active against H. pylori in vitro include mupirocin and newer quinolones such as sitafloxacin and clinafloxacin [44]. Among new patents, benzamide derivatives, pyloricidins (a new family of natural antibiotics), and thienylthiazole derivatives might be useful in the future [44].…”

Section: Future Therapymentioning

confidence: 99%

“…Newer antibiotics active against H. pylori in vitro include mupirocin and newer quinolones such as sitafloxacin and clinafloxacin [44]. Among new patents, benzamide derivatives, pyloricidins (a new family of natural antibiotics), and thienylthiazole derivatives might be useful in the future [44]. Therapeutic vaccination could potentially save millions of lives and be more cost‐effective with fewer potential complications than the administration of multiple antimicrobial agents.…”

Section: Future Therapymentioning

confidence: 99%

Treatment of Helicobacter pylori Infection

et al. 2008

View full text Add to dashboard Cite

Antibiotic resistance has resulted in unsatisfactory eradication results with dual and now triple therapy in many countries. Newer antibiotics and changes in dosing and duration of therapy may overcome resistant strains but may only provide limited improvement in eradication rates. Sequential therapy with amoxicillin (1 g twice a day) and a proton pump inhibitor (PPI) (twice a day) given for 5 days followed by a PPI plus clarithromycin (500 mg twice a day) and tinidazole (500 mg twice a day) for 5 days is now a first-line therapy for Helicobacter pylori in some countries. Standard triple therapy is effective in regions where clarithromycin resistance is low. Levofloxacin based triple therapy is an effective alternative to quadruple therapy in second-line treatment. Adjuvant therapy may reduce side-effects and improve compliance. Molecular and genomic research on H. pylori may result in the development of targeted antibiotic therapy; however, more research is required in this field. Further research in vaccination is also necessary before this can become an option in clinical practice.

show abstract

“…Bismuth salts act by detaching the organism from the mucosa and causing their lyses. These compounds have been generally used as first-line regimens (23). In our study, bismuth salts had a significant role against H. pylori.…”

Section: Discussionmentioning

confidence: 53%

“…The patients should be educated regarding the importance of H. pylori eradication to increase treatment compliance. Primary and acquired bacterial resistance against different antibiotics has been clearly demonstrated and has increased in the last decade (23). Efficacy of first-line therapy is of paramount importance; "rescue" treatments are generally more expensive and less effective.…”

Section: Discussionmentioning

confidence: 99%